

REMARKS

In response to the Restriction Requirement dated October 21, 2003, Applicants elect the invention of claims 8 and 9, drawn to a method for identifying a candidate therapeutic agent for a tuberous sclerosis complex associated disorder in a subject. Applicants further elect TSC122.


In addition, Applicants have cancelled claims 1-7 and 10-19, and Applicants have amended claims 8-9 to cancel subject matter directed to a non-elected invention. Applicants reserve the right to prosecute that subject matter, as well as the originally presented claims, in continuing applications.

Applicants have also added new claims 20-23, drawn to a method for identifying a candidate therapeutic agent for a tuberous sclerosis complex associated disorder in a subject. Support for the methods recited by new claims 20-23 is found throughout the as-filed specification. For example, support for claims 20-23 is found in specification at least at page 4, lines 9-19; in Table 1, specifically at page 10, row 16; at page 49, line 8 through page 52, line 20; and page 60, line 14 through page 61, line 7. Accordingly, no new matter has been added by the amendments presented herein.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,


Ivor R. Elifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623